ClinConnect ClinConnect Logo
Search / Trial NCT06064461

Vitaccess Real MG Registry

Launched by VITACCESS LTD · Sep 26, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Myasthenia Gravis Patient Registry Longitudinal Observational Data

ClinConnect Summary

The Vitaccess Real MG Registry is a long-term study aimed at understanding myasthenia gravis (MG), a condition that affects muscle strength. This registry will collect information from around 600 patients over 10 years to see how MG impacts their daily lives, treatments, and overall quality of life. The data gathered will come from patients and healthcare professionals, and will also include information from medical records to provide a complete picture of the condition.

To be eligible for this study, participants must be at least 18 years old, have a confirmed diagnosis of MG, and live in the US, UK, Germany, France, or Italy. They should also have access to a smartphone, tablet, or computer and be willing to provide informed consent in their local language. Participants can expect to share their experiences and health information regularly, helping researchers learn more about MG and potentially improve treatment options for others in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adult (age ≥18 years) with a clinically-confirmed diagnosis of myasthenia gravis (MG).
  • Resident in one of the scope countries.
  • Access to a smartphone/tablet/computer/laptop
  • Willing and able to provide informed consent in their local language to take part in the study.
  • Exclusion Criteria:
  • Participation in a clinical trial at the time of study enrolment.

About Vitaccess Ltd

Vitaccess Ltd. is a pioneering clinical trial sponsor specializing in innovative digital health solutions that enhance patient engagement and streamline data collection in clinical research. With a focus on leveraging technology to improve the efficiency and effectiveness of clinical trials, Vitaccess employs advanced methodologies, including real-world evidence and patient-reported outcomes, to generate meaningful insights that inform healthcare decision-making. The company's commitment to collaboration and transparency ensures the delivery of high-quality data, ultimately contributing to the acceleration of drug development and improved patient care.

Locations

Houston, Texas, United States

Charleston, South Carolina, United States

Birmingham, , United Kingdom

Oxford, Oxfordshire, United Kingdom

O'fallon, Illinois, United States

London, , United Kingdom

Lexington, Kentucky, United States

Lumberton, New Jersey, United States

Patients applied

0 patients applied

Trial Officials

Mark JW Larkin, PhD

Principal Investigator

Vitaccess Ltd

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported